Attovia Therapeutics, Inc. (ATTO)
Data as of , from SEC Form 4 filings.
Net insider buying (90d)Watch ATTO
See up to 3 months of ATTO. The 7-day demo opens the 1M and 3M ranges and puts ATTO on your watchlist.
Start 7-day demoLatest ATTO insider trades
About Attovia Therapeutics, Inc. (ATTO)
The SEC lists Attovia Therapeutics, Inc. under CIK 0002058707, in biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector. Its offering priced on 5 August 2026 and it trades on NASDAQ.
ATTO Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 25 | 4,422,201 | $77.44M |
| Open-market sale | 92 | 423,228 | $9.01M |
| Grant or award | 8 | 1,690,600 |
ATTO insider transactions (Form 4)
16117 Form 4 filings on record, the earliest from Aug 6, 2026, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Tao Fu - Officer | Grant or award | Stock Option (Right to Buy) | 538,300 | $0.00 | - | |
| Steven Chan - Officer | Grant or award | Stock Option (Right to Buy) | 140,000 | $0.00 | - | |
| Colin Walsh - Director | Open-market purchase | Common Stock | 85,000 | $21.00 | $1.78M | |
| Colin Walsh - Director | Open-market sale | Common Stock | 988 | $22.03 | $22K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 447 | $21.87 | $10K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 1,332 | $22.03 | $29K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 200 | $22.05 | $4K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 1,556 | $22.06 | $34K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 3,402 | $22.02 | $75K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 200 | $22.10 | $4K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 480 | $21.55 | $10K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 100 | $22.11 | $2K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 753 | $21.97 | $17K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 672 | $22.02 | $15K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 6,970 | $22.03 | $154K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 400 | $22.02 | $9K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 1,180 | $21.84 | $26K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 1,040 | $22.05 | $23K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 300 | $20.84 | $6K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 443 | $21.78 | $10K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 200 | $22.05 | $4K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 700 | $22.07 | $15K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 1,163 | $22.19 | $26K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 100 | $21.99 | $2K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 6,763 | $21.61 | $146K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 76,418 | $21.04 | $1.61M | |
| Colin Walsh - Director | Other | Common Stock | 1,957,134 footnote F4,F5 | $0.00 | - | |
| Colin Walsh - Director | Other | Common Stock | 478,498 footnote F4,F5 | $0.00 | - | |
| Colin Walsh - Director | Open-market purchase | Common Stock | 500,000 | $17.00 | $8.50M | |
| Colin Walsh - Director | Other | Series B Preferred Stock | 18,181,830 footnote F5 | $0.00 | - | |
| Colin Walsh - Director | Other | Series C Preferred Stock | 4,445,275 footnote F5 | $0.00 | - | |
| Colin Walsh - Director | Open-market purchase | Equity Swap | 2,872 | $21.22 | $61K | |
| Colin Walsh - Director | Open-market purchase | Equity Swap | 28,717 | $21.22 | $609K | |
| Colin Walsh - Director | Open-market purchase | Equity Swap | 11,488 | $21.22 | $244K | |
| Colin Walsh - Director | Open-market purchase | Equity Swap | 45,588 | $21.27 | $970K | |
| Colin Walsh - Director | Open-market purchase | Equity Swap | 11,398 | $21.27 | $242K | |
| Colin Walsh - Director | Open-market purchase | Equity Swap | 5,744 | $21.22 | $122K | |
| ||||||
| GOLDMAN SACHS GROUP INC | Open-market purchase | Common Stock | 85,000 | $21.00 | $1.78M | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 988 | $22.03 | $22K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 447 | $21.87 | $10K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 1,332 | $22.03 | $29K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 200 | $22.05 | $4K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 1,556 | $22.06 | $34K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 3,402 | $22.02 | $75K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 200 | $22.10 | $4K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 480 | $21.55 | $10K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 100 | $22.11 | $2K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 753 | $21.97 | $17K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 672 | $22.02 | $15K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 6,970 | $22.03 | $154K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 400 | $22.02 | $9K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 1,180 | $21.84 | $26K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 1,040 | $22.05 | $23K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 300 | $20.84 | $6K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 443 | $21.78 | $10K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 200 | $22.05 | $4K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 700 | $22.07 | $15K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 1,163 | $22.19 | $26K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 100 | $21.99 | $2K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 6,763 | $21.61 | $146K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 76,418 | $21.04 | $1.61M | |
| GOLDMAN SACHS GROUP INC | Other | Common Stock | 1,957,134 footnote F4,F5 | $0.00 | - | |
| GOLDMAN SACHS GROUP INC | Other | Common Stock | 478,498 footnote F4,F5 | $0.00 | - | |
| GOLDMAN SACHS GROUP INC | Open-market purchase | Common Stock | 500,000 | $17.00 | $8.50M | |
| GOLDMAN SACHS GROUP INC | Other | Series B Preferred Stock | 18,181,830 footnote F5 | $0.00 | - | |
| GOLDMAN SACHS GROUP INC | Other | Series C Preferred Stock | 4,445,275 footnote F5 | $0.00 | - | |
| GOLDMAN SACHS GROUP INC | Open-market purchase | Equity Swap | 2,872 | $21.22 | $61K | |
| GOLDMAN SACHS GROUP INC | Open-market purchase | Equity Swap | 28,717 | $21.22 | $609K | |
| GOLDMAN SACHS GROUP INC | Open-market purchase | Equity Swap | 11,488 | $21.22 | $244K | |
| GOLDMAN SACHS GROUP INC | Open-market purchase | Equity Swap | 45,588 | $21.27 | $970K | |
| GOLDMAN SACHS GROUP INC | Open-market purchase | Equity Swap | 11,398 | $21.27 | $242K | |
| GOLDMAN SACHS GROUP INC | Open-market purchase | Equity Swap | 5,744 | $21.22 | $122K | |
| ||||||
| Colin Walsh - Director | Open-market purchase | Common Stock | 85,000 | $21.00 | $1.78M | |
| Colin Walsh - Director | Open-market sale | Common Stock | 988 | $22.03 | $22K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 447 | $21.87 | $10K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 1,332 | $22.03 | $29K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 200 | $22.05 | $4K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 1,556 | $22.06 | $34K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 3,402 | $22.02 | $75K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 200 | $22.10 | $4K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 480 | $21.55 | $10K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 100 | $22.11 | $2K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 753 | $21.97 | $17K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 672 | $22.02 | $15K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 6,970 | $22.03 | $154K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 400 | $22.02 | $9K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 1,180 | $21.84 | $26K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 1,040 | $22.05 | $23K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 300 | $20.84 | $6K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 443 | $21.78 | $10K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 200 | $22.05 | $4K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 700 | $22.07 | $15K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 1,163 | $22.19 | $26K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 100 | $21.99 | $2K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 6,763 | $21.61 | $146K | |
| Colin Walsh - Director | Open-market sale | Common Stock | 76,418 | $21.04 | $1.61M | |
| Colin Walsh - Director | Other | Common Stock | 1,957,134 footnote F4,F5 | $0.00 | - | |
| Colin Walsh - Director | Other | Common Stock | 478,498 footnote F4,F5 | $0.00 | - | |
| Colin Walsh - Director | Open-market purchase | Common Stock | 500,000 | $17.00 | $8.50M | |
| Colin Walsh - Director | Other | Series B Preferred Stock | 18,181,830 footnote F5 | $0.00 | - | |
| Colin Walsh - Director | Other | Series C Preferred Stock | 4,445,275 footnote F5 | $0.00 | - | |
| ||||||
| GOLDMAN SACHS GROUP INC | Open-market purchase | Common Stock | 85,000 | $21.00 | $1.78M | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 988 | $22.03 | $22K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 447 | $21.87 | $10K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 1,332 | $22.03 | $29K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 200 | $22.05 | $4K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 1,556 | $22.06 | $34K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 3,402 | $22.02 | $75K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 200 | $22.10 | $4K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 480 | $21.55 | $10K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 100 | $22.11 | $2K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 753 | $21.97 | $17K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 672 | $22.02 | $15K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 6,970 | $22.03 | $154K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 400 | $22.02 | $9K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 1,180 | $21.84 | $26K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 1,040 | $22.05 | $23K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 300 | $20.84 | $6K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 443 | $21.78 | $10K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 200 | $22.05 | $4K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 700 | $22.07 | $15K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 1,163 | $22.19 | $26K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 100 | $21.99 | $2K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 6,763 | $21.61 | $146K | |
| GOLDMAN SACHS GROUP INC | Open-market sale | Common Stock | 76,418 | $21.04 | $1.61M | |
| GOLDMAN SACHS GROUP INC | Other | Common Stock | 1,957,134 footnote F4,F5 | $0.00 | - | |
| GOLDMAN SACHS GROUP INC | Other | Common Stock | 478,498 footnote F4,F5 | $0.00 | - | |
| GOLDMAN SACHS GROUP INC | Open-market purchase | Common Stock | 500,000 | $17.00 | $8.50M | |
| GOLDMAN SACHS GROUP INC | Other | Series B Preferred Stock | 18,181,830 footnote F5 | $0.00 | - | |
| GOLDMAN SACHS GROUP INC | Other | Series C Preferred Stock | 4,445,275 footnote F5 | $0.00 | - | |
| ||||||
| Deep Track Biotechnology Master Fund, Ltd. - 10% Owner | Other | Common Stock | 1,957,138 | - footnote F1 | - | |
| Deep Track Biotechnology Master Fund, Ltd. - 10% Owner | Other | Series C Redeemable Convertible Preferred Stock | 18,181,818 | $0.00 | - | |
| ||||||
| venBio Global Strategic Fund IV, L.P. - 10% Owner | Other | Common Stock | 2,311,870 | - footnote F1 | - | |
| venBio Global Strategic Fund IV, L.P. - 10% Owner | Other | Common Stock | 821,998 | - footnote F1 | - | |
| venBio Global Strategic Fund IV, L.P. - 10% Owner | Other | Common Stock | 665,147 | - footnote F1 | - | |
| venBio Global Strategic Fund IV, L.P. - 10% Owner | Open-market purchase | Common Stock | 382,352 | $17.00 | $6.50M | |
| venBio Global Strategic Fund IV, L.P. - 10% Owner | Other | Series A Preferred Stock | 21,477,273 | $0.00 | - | |
| venBio Global Strategic Fund IV, L.P. - 10% Owner | Other | Series B Preferred Stock | 7,636,362 | $0.00 | - | |
| venBio Global Strategic Fund IV, L.P. - 10% Owner | Other | Series C Preferred Stock | 6,179,219 | $0.00 | - | |
| ||||||
| Redmile Group, LLC - 10% Owner | Other | Common Stock | 782,854 | - footnote F1 | - | |
| Redmile Group, LLC - 10% Owner | Open-market purchase | Common Stock | 200,000 | $17.00 | $3.40M | |
| Redmile Group, LLC - 10% Owner | Open-market purchase | Common Stock | 400,000 | $17.00 | $6.80M | |
| Redmile Group, LLC - 10% Owner | Other | Series B Preferred Stock | 782,854 | - footnote F1 | - | |
| ||||||
| Sanofi - 10% Owner | Other | Common Stock | 782,855 | - footnote F1 | - | |
| Sanofi - 10% Owner | Open-market purchase | Common Stock | 300,000 | $17.00 footnote F2 | $5.10M | |
| Sanofi - 10% Owner | Other | Series C Preferred Stock | 782,855 | - footnote F1 | - | |
| ||||||
| Frazier Life Sciences XI, L.P. - 10% Owner | Other | Common Stock | 1,749,192 | - footnote F1 | - | |
| Frazier Life Sciences XI, L.P. - 10% Owner | Other | Common Stock | 1,590,175 | - footnote F3 | - | |
| Frazier Life Sciences XI, L.P. - 10% Owner | Other | Common Stock | 1,189,940 | - footnote F4 | - | |
| Frazier Life Sciences XI, L.P. - 10% Owner | Other | Common Stock | 961,322 | - footnote F5 | - | |
| Frazier Life Sciences XI, L.P. - 10% Owner | Open-market purchase | Common Stock | 588,235 | $17.00 | $10.00M | |
| Frazier Life Sciences XI, L.P. - 10% Owner | Other | Series A-1 Preferred Stock | 16,250,000 | $0.00 | - | |
| Frazier Life Sciences XI, L.P. - 10% Owner | Other | Series A-2 Preferred Stock | 14,772,727 | $0.00 | - | |
| Frazier Life Sciences XI, L.P. - 10% Owner | Other | Series B Preferred Stock | 11,054,544 | $0.00 | - | |
| Frazier Life Sciences XI, L.P. - 10% Owner | Other | Series C Preferred Stock | 8,930,685 | $0.00 | - | |
| ||||||
| Angie You - Director | Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | |
| Mitchell Gold - Director | Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | |
| Zaneta Odrowaz - Officer | Grant or award | Stock Option (Right to Buy) | 140,000 | $0.00 | - | |
| Petter Veiby - Officer | Grant or award | Stock Option (Right to Buy) | 140,000 | $0.00 | - | |
| Hubert Chen - Officer | Grant or award | Stock Option (Right to Buy) | 140,000 | $0.00 | - | |
| Attovia Therapeutics, Inc. - Officer | Grant or award | Stock Option (Right to Buy) | 538,300 | $0.00 | - | |
Item 2.02, 9.01
Item 5.03, 9.01
Recent ATTO Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | Former 10% Owner | 105,807 | $2.22M | View on EDGAR |
ATTO insider trading FAQ
What is the latest insider trade for ATTO?
Attovia Therapeutics, Inc. (ATTO) had 17 insider filings in the last 90 days, with the most recent on 9 October 2026. The full record for ATTO runs to 17 Form 4 filings, the earliest from 6 August 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ATTO stock?
25 insider purchases of ATTO were filed in the last 90 days, totaling $77.44M.
How many insiders are selling ATTO stock?
92 insider sales of ATTO were filed in the last 90 days, totaling $9.01M.
Where can I see ATTO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ATTO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Tao Fu view on EDGAR
- - Steven Chan view on EDGAR
- - Colin Walsh view on EDGAR
- - GOLDMAN SACHS GROUP INC view on EDGAR
- - Colin Walsh view on EDGAR
- - GOLDMAN SACHS GROUP INC view on EDGAR
- - Deep Track Biotechnology Master Fund, Ltd. view on EDGAR
- - venBio Global Strategic Fund IV, L.P. view on EDGAR
- - Redmile Group, LLC view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ATTO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ATTO with a 7-day demo
- ATTO on your watchlist
- Every ATTO Form 4 filing on record
- Up to 3 months of ATTO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
